Since Merck’s patent for Fosamax® (alendronate) expired in early 2008, the company has been seeking to fill the gap in its osteoporosis pipeline. A deal signed with Japan Tobacco for its bone growth stimulator drug, JTT-305, is one of the novel approaches that Merck is pursuing.